Key Milestones Achieved and Future Plans Discussed in CorMedix (CRMD) Q1 2024 Earnings Call
Thursday, 9 May 2024, 15:00
CorMedix (CRMD) Q1 2024 Earnings Call Highlights:
Key Achievements:
- Obtained CMS approval for DefenCath and started inpatient commercial launch
- Initiated outpatient procurement contracts and discussed label expansion plans
- Submitted supplement for alternate manufacturer in the supply chain
Financial Results:
- Net loss increased driven by higher operating expenses
- Operating expenses rose, primarily due to growth and commercial launch costs
- Net cash used in operations increased, but cash position improved to support operations
CorMedix aims for breakeven profitability in 2024, with a focus on commercial execution and financial flexibility.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.